Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + induction chemotherapy and concurrent chemoradiation in advanced esophageal carcinoma
ChiCTR2100046715Phase 2Recruiting
- Sponsor
- Sichuan Cancer Hospital & Institute
- Start
- Jun 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sichuan Cancer Hospital & Institute. Primary endpoints: Progression-free survival and Overall response rate. Started Jun 2021; status: recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2100046715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046715.